ProQR Therapeutics (NASDAQ:PRQR) Cut to “Sell” at StockNews.com

StockNews.com cut shares of ProQR Therapeutics (NASDAQ:PRQR) from a hold rating to a sell rating in a research report report published on Thursday morning.

PRQR has been the subject of a number of other reports. HC Wainwright lifted their price objective on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James raised shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $7.13.

ProQR Therapeutics Trading Up 4.6 %

Shares of PRQR opened at $3.84 on Thursday. ProQR Therapeutics has a 12-month low of $1.35 and a 12-month high of $4.62. The company has a market cap of $313.65 million, a PE ratio of -12.00 and a beta of 0.26. The stock has a 50-day moving average price of $3.08 and a 200-day moving average price of $2.29.

Hedge Funds Weigh In On ProQR Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRQR. Privium Fund Management B.V. grew its position in shares of ProQR Therapeutics by 4.4% in the 2nd quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock worth $9,208,000 after buying an additional 236,279 shares during the period. OneDigital Investment Advisors LLC boosted its stake in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 15,550 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 7,300 shares during the period. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).